Previous 10 | Next 10 |
Intercept Pharma (ICPT): Q3 GAAP EPS of -$2.01 misses by $0.04.Revenue of $79.52M (+28.4% Y/Y) beats by $0.92M.2020 guidance: Ocaliva net sales: $310M - 320M from $300M - 320M.Press Release For further details see: Intercept Pharma EPS misses by $0.04, beats on revenue
Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over the prior year quarter Intercept updates 2020 Ocaliva Net Sales Guidance to narrow the range to $310 million to $320 million Intercept updates 2020 non-GAAP Adjusted Oper...
[[ALE]], [[BCOR]], [[BHVN]], [[BIP]], [[BKI]], [[BTU]], [[CARS]], [[CGC]], [[CNNE]], [[EBIX]], [[GOGO]], [[HL]], [[HWM]], [[ICPT]], [[MCD]], [[PLUG]], [[RDNT]], [[RETA]], [[TGNA]]For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings bef...
Intercept Pharma (NASDAQ:ICPT) is scheduled to announce Q3 earnings results on Monday, November 9th, before market open.The consensus EPS Estimate is -$1.94 (+25.1% Y/Y) and the consensus Revenue Estimate is $78.6M (+26.9% Y/Y).Analyst expects 3Q net Ocaliva sales of $77.0M.Over the last...
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2020 financial results...
OCA, Intercept’s only commercialized product, is undergoing an FDA investigation on its safety. Once battered by a failed FDA approval for OCA as a NASH therapy, the stock slumped to trade near a 52-week low last week. The top-line growth hurt by the pandemic’s impac...
Intercept Pharmaceuticals ([[ICPT]] -5.1%) is down on 60% higher volume in reaction to a report that the FDA is investigating a potential safety signal related to Ocaliva (obeticholic acid), specifically, the risk of liver injury. The inquiry began in May and could take a year to complete.The...
Gainers: [[SPI]] +58.3%. [[MCHX]] +16.1%. [[JEF]] +8.9%. [[PRVB]] +8.8%. [[DPW]] +3.5%.Losers: [[WNC]] -3.5%. [[PEAK]] -3.3%. [[ICPT]] -2.8%. [[NNOX]] -2.4%. [[BEKE]] -2.2%. For further details see: SPI, JEF, PEAK and ICPT among after-hours movers
Intercept Pharmaceuticals (NASDAQ: ICPT) is like a lot of biopharmaceutical stocks: It's not making money, but all it takes is one major drug to turn things around. Intercept, founded in 2002 and headquartered in New York City, focuses on the treatment of progressive non-viral liver disease...
Quick Take Metacrine ( MTCR ) intends to raise $85 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for NASH conditions. MTCR is entering Phase 2 trials and will have significant capital ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...